Cluster of differentiation-22 (CD22) belongs to the sialic acid-binding immunoglobulin (Ig)-like lectin family of receptors that is expressed on the surface of B cells. It has been classified as an inhibitory coreceptor for the B-cell receptor because of its function in establishing a baseline level of B-cell inhibition. The restricted expression of CD22 on B cells and its inhibitory function make it an attractive target for B-cell depletion in cases of B-cell malignancies. Genetically modified T cells with chimeric antigen receptors (CARs) derived from the m971 antibody have shown promise when used as an immunotherapeutic agent against B-cell acute lymphoblastic leukemia. A key aspect of the efficacy of this CAR-T was its ability to target a membrane-proximal epitope on the CD22 extracellular domain; however, the molecular details of m971 recognition of CD22 have thus far remained elusive. Here, we report the crystal structure of the m971 fragment antigen-binding in complex with the two most membrane-proximal Ig-like domains of CD22 (CD22). The m971 epitope on CD22 resides at the most proximal Ig domain (d7) to the membrane, and the antibody paratope contains electrostatic surfaces compatible with interactions with phospholipid head groups. Together, our data identify molecular details underlying the successful transformation of an antibody epitope on CD22 into an effective CAR immunotherapeutic target.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353475 | PMC |
| http://dx.doi.org/10.1016/j.jbc.2021.100966 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22.
Mol Ther Oncol
March 2024
Human Health Therapeutics Research Centre, National Research Council, Ottawa, ON, Canada.
Chimeric antigen receptor (CAR) T cell therapies targeting B cell-restricted antigens CD19, CD20, or CD22 can produce potent clinical responses for some B cell malignancies, but relapse remains common. Camelid single-domain antibodies (sdAbs or nanobodies) are smaller, simpler, and easier to recombine than single-chain variable fragments (scFvs) used in most CARs, but fewer sdAb-CARs have been reported. Thus, we sought to identify a therapeutically active sdAb-CAR targeting human CD22.
View Article and Find Full Text PDFHigh yield killing of lymphoma cells by anti-CD22 CAR-NK cell therapy.
In Vitro Cell Dev Biol Anim
April 2024
Hematology and Cell Therapy Department, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Chimeric antigen receptors (CARs) offer a promising new approach for targeting B cell malignancies through the immune system. Despite the proven effectiveness of CAR T cells targeting CD19 and CD22 in hematological malignancies, it is imperative to note that their production remains a highly complex process. Unlike T cells, NK cells eliminate targets in a non-antigen-specific manner while avoiding graft vs.
View Article and Find Full Text PDFGenomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Blood
July 2024
Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Article Synopsis
- * The study found that 11% of patients who relapsed after InO developed mutations in the CD22 gene, which allowed cancer cells to evade treatment, often through losing or altering the CD22 protein's structure.
- * Additional mutations were also seen in genes related to DNA damage response, raising concerns about how cancer cells adapt post-treatment, emphasizing the need for understanding these mechanisms to improve future therapies, especially before procedures like stem cell transplantation.
Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy.
J Immunother Cancer
February 2024
Convergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California, USA
Background: Chimeric antigen receptor (CAR)-T cells are approved for use in the treatment of hematological malignancies. Axicabtagene ciloleucel (YESCARTA) and brexucabtagene autoleucel (TECARTUS) genetically modified autologous T cells expressing an anti-CD19 scFv based on the FMC63 clone have shown impressive response rates for the treatment of CD19+B cell malignancies, but there remain challenges in monitoring long-term persistence as well as the functional characterization of low-level persisting CAR-T cells in patients. Furthermore, due to CD19-negative driven relapse, having the capability to monitor patients with simultaneous detection of the B cell malignancy and persisting CAR-T cells in patient peripheral blood is important for ensuring timely treatment optionality and understanding relapse.
View Article and Find Full Text PDFArticle Synopsis
- Inotuzumab ozogamicin (InO) is a targeted therapy for B-cell acute lymphoblastic leukemia that delivers a cytotoxic drug to cells expressing the CD22 antigen.
- A study on patients treated with InO revealed that approximately 11% exhibited genomic mutations contributing to treatment resistance, with various escape mechanisms like protein truncation and destabilization.
- The findings highlight the role of DNA damage repair processes in promoting CD22 mutations and suggest that understanding these genetic changes can help improve treatment strategies for overcoming resistance to therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!